HIGHLIGHTS
- who: Tsukasa Yoshida from the Medicine (PCOM), United States Keio University School of Medicine have published the research work: Long response duration to pembrolizumab in metastatic, castration-resistant prostate cancer with microsatellite instability-high and neuroendocrine differentiation: A case report, in the Journal: (JOURNAL)
- what: This report discusses a patient with a long-term response to pembrolizumab in CRPC-NE with MSI-high.
SUMMARY
Small cell/neuroendocrine (NE) differentiation in prostate cancer can appear de novo in untreated patients but is relatively rare ( and amp;lt;2%). More commonly, NE differentiation . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.